Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Sees Large Growth in Short Interest

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 256,400 shares, an increase of 140.3% from the December 31st total of 106,700 shares. Based on an average trading volume of 164,600 shares, the days-to-cover ratio is presently 1.6 days. Currently, 4.1% of the shares of the company are sold short.

Bullfrog AI Price Performance

Shares of BFRG traded up $0.38 during trading hours on Thursday, reaching $2.65. 938,205 shares of the company’s stock traded hands, compared to its average volume of 465,087. The business’s fifty day simple moving average is $2.23 and its two-hundred day simple moving average is $2.45. The firm has a market capitalization of $23.08 million, a price-to-earnings ratio of -3.12 and a beta of 0.13. Bullfrog AI has a twelve month low of $1.43 and a twelve month high of $5.89.

Bullfrog AI (NASDAQ:BFRG) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.22) earnings per share for the quarter.

Institutional Investors Weigh In On Bullfrog AI

An institutional investor recently bought a new position in Bullfrog AI stock. Renaissance Technologies LLC acquired a new stake in shares of Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 19,800 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.25% of Bullfrog AI at the end of the most recent quarter. Institutional investors own 0.96% of the company’s stock.

Bullfrog AI Company Profile

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.